|
Sep 18, 2026
|
FORT LAUDERDALE, Fla., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (Nasdaq: TCRT) today announced that it has entered into definitive agreements with institutional investors in a registered direct offering for the sale of 380,469 shares of its common stock and pre-funded warrants
|
|
|
Jun 29, 2026
|
This statistical finding supports a lower liver-weight signal after adjustment for body fat percentage, suggesting the finding was not fully explained by measured body fat in this model Liver-weight findings are directionally consistent with previously disclosed data on lower liver injury enzymes,
|
|
|
May 26, 2026
|
ALN1003 demonstrated consistent, favorable effects across key drivers of metabolic disease, including reductions in body weight and fat mass, improved insulin sensitivity, enhanced adipose function, and improved liver health in diet-induced obese mice A non-confidential investor presentation
|
|
|
May 18, 2026
|
Findings from non-GLP DIO mouse studies show effects on insulin-resistance-related biomarkers, adipose endocrine signaling, and qualitative liver histology findings consistent with lower hepatic steatosis FORT LAUDERDALE, Fla., May 18, 2026 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc.
|
|
|
Mar 02, 2026
|
The lead drug candidate, ALN1003, showed dose-related body weight loss and favorable body composition changes in the DIO mouse model ALN1003 also demonstrated reductions in liver weight and improvements in select biomarkers associated with liver injury compared to untreated mice Efforts to conduct
|
|
